|
Patient Demographics Based on Fibrosis Staging. |
||
| METAVIR Stage |
||
|
|
||
| F0-F1 |
F3-F4 |
|
|
|
||
| Age (y) |
43.8 ± 9.75 |
48.1 ± 4.18 |
| Sex (M/F) |
21/2 |
19/2 |
| Race |
||
| White |
20 |
19 |
| Hispanic |
2 |
2 |
| Asian |
1 |
0 |
| HCV genotype |
||
| 1 |
18 |
14 |
| 2 |
3 |
2 |
| 3 |
2 |
5 |
| Duration of infection (y) |
22.1 ± 6.03 |
22.9 ± 6.68 |
| ALT (IU/mL) |
101.7 ± 61.64a |
129.8 ± 69.19b |
| METAVIR Activity |
1 (0–3)c |
2 (0–3)d |
|
|
||
| HCV RNA (log10 copies/mL) |
6.53 ± 0.39 |
6.43 ± 0.43 |
|
Results shown as mean ± standard deviation, number, or median (range); ALT, alanine aminotransferase; HCV, hepatitis C virus; METAVIR Activity, histological score of necroinflammation based on interface, lobular, and portal inflammation. a vs. b, p = 0.16; c vs. d, p = 0.07 | ||
White et al. Journal of Translational Medicine 2007 5:33 doi:10.1186/1479-5876-5-33 |
||